Literature DB >> 17461808

Eruptive post-chemotherapy in situ melanomas and dysplastic nevi.

Jason C Reutter1, Erin M Long, Dean S Morrell, Nancy E Thomas, Pamela A Groben.   

Abstract

A 22-year-old white man without a personal or family history of atypical nevi had received chemotherapy for pre-B-cell acute lymphocytic leukemia at age 17 that included L-asparaginase, prednisone, methotrexate, mercaptopurine, daunorubicin, and cytoxan. Two to three months after completing maintenance chemotherapy, the patient reports he developed many moles, which remained stable for approximately 2 years. Upon examination, two dark, atypical appearing plaques with irregular borders and numerous pink papules of varying shapes and sizes were noted on his chest, back, and abdomen. Histology of specimens of both types of lesions revealed three moderately atypical compound dysplastic melanocytic nevi and three in situ melanomas. The lesions with only features of dysplastic nevi exhibited dermal fibrosis, cytologic atypia, junctional shoulders, lentiginous spread, and focal pigmentation. The lesions with in situ melanomas in addition demonstrated pagetoid spread, extension down adnexal structures, and more severe cytologic atypia. Malignant melanoma has been associated with chronic immunosuppression, and benign nevi have been reported to erupt after chemotherapy. We report an occurrence of multiple eruptive dysplastic nevi and in situ melanomas appearing shortly after completion of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17461808     DOI: 10.1111/j.1525-1470.2007.00359.x

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  7 in total

1.  Sorafenib-induced eruptive melanocytic lesions.

Authors:  Heidi H Kong; Vincent Sibaud; Maria L Chanco Turner; Tito Fojo; Thomas J Hornyak; Christine Chevreau
Journal:  Arch Dermatol       Date:  2008-06

2.  The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

3.  Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.

Authors:  Philip R Cohen; Agop Y Bedikian; Kevin B Kim
Journal:  J Clin Aesthet Dermatol       Date:  2013-05

4.  Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review.

Authors:  P Dillon; N Thomas; N Sharpless; F Collichio
Journal:  Med Oncol       Date:  2009-11-05       Impact factor: 3.064

5.  A case with postchemotherapy eruptive compound nevus.

Authors:  Selma Bakar Dertlioglu; Muharrem Bitiren; Demet Cicek
Journal:  Indian J Dermatol       Date:  2011-11       Impact factor: 1.494

6.  Dysplastic Nevus with Eruptive Melanocytic Lesions That Developed during Nilotinib Therapy for Chronic Myeloid Leukemia.

Authors:  Joo Hyun Lee; Jin Hee Kang; Baik Kee Cho; Hyun Jeong Park
Journal:  Ann Dermatol       Date:  2015-12-07       Impact factor: 1.444

Review 7.  Congenital Glioblastoma multiforme and eruptive disseminated Spitz nevi.

Authors:  Victor Desmond Mandel; Flavia Persechino; Alberto Berardi; Giovanni Ponti; Silvana Ciardo; Cecilia Rossi; Giovanni Pellacani; Francesca Farnetani
Journal:  Ital J Pediatr       Date:  2016-05-14       Impact factor: 2.638

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.